Project Grant K01AI182501
Award Date
9/4/24
Completion Date
8/31/29
Dollars Obligated
$135K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Berkeley, CA 94720, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $563,588.00 to investigate the effects of immunosuppression on SARS-CoV-2 persistence, virus genetic diversity, and COVID-19 clinical outcomes. The study aims to determine the specific immune defects linked to prolonged SARS-CoV-2 replication and acute disease, as well as the effect of different...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $380,320.00 to support research focused on understanding human CD8 T cell responses to SARS-CoV-2 and how CD8 T cell dysfunction may contribute to the development of Long COVID. The key research objectives are to: 1) define the lineages and differentiation trajectories of functionally distinct CD8 T cell populations...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $148,824 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Research Foundation of the City University of New York (RFCUNY) - Graduate School of Public Health and Health Policy. This 5-year grant, awarded on Aug 2, 2024, will fund research to understand the clinical and social factors impacting HIV and COVID-19 outcomes among people with HIV (PWH), and characterize how the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $333,556 to the University of San Francisco (USF) to characterize the severity of SARS-CoV-2 co-infections and the effects of COVID-19 vaccination on disease severity in a cohort of over 100,965 SARS-CoV-2-infected U.S. children. The project aims to provide more comprehensive evidence on the burden of...
This federal Project Grant award of $124,319 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research aimed at defining factors affecting natural killer (NK) cells' antibody-dependent responses to SARS-CoV-2, the virus causing COVID-19. The research seeks to 1) identify how COVID-19 vaccination and infection influence memory-like NK cells' antibody-dependent responses, 2) elucidate how...
This federal Project Grant award of $198,720 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research to improve understanding of post-infectious dysautonomia, a common and disabling syndrome that can occur following COVID-19 and Lyme disease. The key products and services to be delivered include: Prospective clinical evaluation of patients with confirmed post-acute sequelae of COVID-19...
This federal Project Grant award from the Department of Health and Human Services National Institutes of Health Office of the Director provided $14,427,699 to New York University School of Medicine for the period of May 24, 2021 through May 23, 2022. The award was made under the Lung Diseases Research program (CFDA #93.838) to support the POST-ACUTE SEQUELAE OF SARS-COV-2 INFECTION INITIATIVE: NYU LANGONE HEALTH CLINICAL SCIENCE CORE, DATA RESOURCE CORE, AND PASC BIOREPOSITORY CORE....
This $192,888 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support a research study to evaluate the generation, differentiation, breadth, and persistence of SARS-CoV-2-specific CD4+ and CD8+ T cell responses in patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). The goal is to provide in-depth knowledge on how antigen-specific T cell responses...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $448,875 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of California, Los Angeles (UCLA) to investigate the use of the GABAA receptor agonist homotaurine as a potential therapy for long-term neurological complications associated with SARS-CoV-2 infection, referred to as "long COVID". The research will be conducted in a hamster model to test the hypothesis that...
This $711,555 federal Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop highly interpretable and predictive modeling frameworks for understanding the spatiotemporal transmission dynamics and control of vaccine-preventable childhood infections. The key objectives are to: 1) Integrate graph neural networks with compartmental models to create a flexible,...